-
Featured
Advancements in the Treatment of Neurodegenerative Disease
In this video, Ghazaleh Sadri-Vakili, PhD, director of the NeuroEpigenetics Laboratory and the MassGeneral Institute of Neurodegenerative Disease, discusses her genetic research, specifically concerning neurodegenerative diseases like ALS and X-linked dystonia parkinsonism.
-
Featured
Tau PET Imaging May Help Identify People with Pre-symptomatic Alzheimer’s Disease
Brain changes associated with Alzheimer’s disease can now be studied in living people. Mass General researchers imaged cognitively normal people who are destined to develop AD due to a rare genetic mutation. Their goal: to discover how soon brain changes are present before symptoms begin and how soon preventive treatments could be initiated.
-
Featured
Identifying New Potential Therapeutic Targets for ALS FTD
Transcripts of repeat expansions in the C90RF72 gene undergo a repeat-associated non-AUG (RAN) translation pathway that generates multiple aberrant proteins. Researchers at Mass General Hospital identified new potential therapeutic targets for ALS FTD.
-
Using Biomarkers to Predict and Prevent Alzheimer's Disease
Yakeel T. Quiroz, PhD, is the director of the Familial Dementia Neuroimaging Laboratory at Massachusetts General Hospital. For the past several years, she has been studying a Columbian family with autosomal dominant Alzheimer's disease. In this video, she discusses her research to find biomarkers that signal early brain changes associated with developing Alzheimer's Disease.
-
Scientists Identify Steps Needed to Address Disparities in Dementia Research and Care
According to a white paper sponsored by the Alzheimer's Association, dementia scientists must stop neglecting the need for research on underrepresented ethnic and racial groups.
-
Researchers Identify a New Therapeutic Target for TDP-43-mediated Neurodegenerative Diseases
Loss of TDP-43 nuclear function is a major event in ALS pathogenesis and leads to widespread RNA processing alterations including reduced stathmin-2 levels. Stathmin-2 is shown to be crucial for axonal regeneration and to represent a novel therapeutic target in ALS.
Learn more about the MassGeneral Institute for Neurodegenerative Disease
Neurodegenerative Disease contributors
-
Ghazaleh Sadri-Vakili, MS, PhD
Assistant in Neuroscience, Massachusetts General Hospital, Assistant Professor of Neurology, Harvard Medical School
Recent Article
Potential New Drug Target for Huntington's Disease Identified
-
Joel A. Salinas, MD, MSc, MBA
Chief, McCance Brain Health Unit
Recent Article
Social Relationships May Influence Stroke and Dementia Risk
-
Jonathan Rosand, MD
Co-Director, Henry and Allison McCance Center for Brain Health, Chief, Division of Neurocritical Care and Emergency Neurology, Medical Director, Neuroscience Intensive Care Unit
Recent Article
Genetic Variation and Risk of Stroke
-
Keith A. Johnson, MD
Radiologist
Recent Article
Tau PET Imaging May Help Identify People with Pre-symptomatic Alzheimer’s Disease
-
Yakeel T. Quiroz-Gaviria, PhD
Co-Director, MGH Multicultural Neuropsychology Program (MUNDOS)
Recent Article
Using Biomarkers to Predict and Prevent Alzheimer's Disease
Neuroscience Care at Mass General
Through a combination of unmatched expertise, creativity and compassion, Mass General Neuroscience relentlessly advances the fields of Neurosurgery, Neurology and Psychiatry to unleash our patients’ potential.Resource Links
